# Japan Rapid Diagnostics Market > Japan Rapid Diagnostics Market Research Report By Application (Blood Glucose Testing, Infectious Disease Testing, Cardiometabolic Testing, Pregnancy Fertility Testing, Fecal Occult Blood Testing, Coagulation Testing, Toxicology Testing) and By Product Type (Over the Counter (OTC) Kits, Professional Kits) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.8% - **2024:** $ 1,414.93 Million - **2025:** $ 1,539.45 Million - **2035:** $ 3,577 Million - **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), bioMérieux (FR), Cepheid (US), Hologic, Inc. (US), Ortho Clinical Diagnostics (US) **Report ID:** MRFR/MED/43665-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/japan-rapid-diagnostics-market-45345 --- ## Market Summary ## **Japan Rapid Diagnostics Market Overview** As per MRFR analysis, the Japan Rapid Diagnostics Market Size was estimated at 867.0 (USD Million) in 2023.The Japan Rapid Diagnostics Market Industry is expected to grow from 942.0(USD Million) in 2024 to 2,826.0 (USD Million) by 2035. The Japan Rapid Diagnostics Market CAGR (growth rate) is expected to be around 10.503% during the forecast period (2025 - 2035). **Key Japan Rapid Diagnostics Market Trends Highlighted** The Japanese rapid diagnostics market is rapidly growing, mainly due to the increased need for timely medical attention and the aged population. The increase in chronic and infectious diseases has raised the need for fast and accurate diagnostic solutions, resulting in rapid tests becoming paramount within healthcare. The increasing adoption of healthcare technology serves as a window opportunity for more sophisticated products. There is an increase in confidence with home and point-of-care testing, where patients and providers are able to obtain results immediately, enabling quick treatment decisions to be made. Recent shifts indicate that the use of digital health technologies, including telemedicine and electronic health record systems integrated with rapid diagnostics, has increased. This enables remote patient monitoring and more effective disease control, resulting in better healthcare delivery. Moreover, the prominent pharmaceutical and biotech industries in Japan consistently engage in R&D, creating new opportunities for rapid diagnostic tests that are compliant with existing local standards and regulations. As the market shifts, there is a rising focus and emphasis on partnerships and collaborations among different stakeholders in Japan to improve product and market diversification. **Japan Rapid Diagnostics Market Drivers** **Rising Demand for Point-of-Care Testing** The Japan Rapid Diagnostics Market Industry is experiencing a surge in demand for point-of-care testing devices as healthcare professionals seek to provide quick and accurate patient feedback. According to a report from the Ministry of Health, Labour and Welfare of Japan, the prevalence of chronic diseases is rising, with the number of diabetes patients expected to reach over 10 million by 2030, increasing the necessity for rapid diagnostic testing.Organizations like the Japan Diabetes Society are actively promoting the adoption of rapid diagnostic tests to improve patient management and outcomes. The growing trend towards decentralization of healthcare, coupled with higher expectations from patients for rapid service delivery, further fuels the demand for these diagnostics, enhancing growth prospects in this market segment. **Advancements in Biotechnology and R** The Japan Rapid Diagnostics Market Industry is being significantly propelled by advancements in biotechnology and research and development activities. The Japanese government has initiated several funding schemes aimed at fostering innovation in this sector, which has led to increased patent filings in rapid diagnostics technologies. The Japan Patent Office reports a steady increase in biotechnological patent applications, reaching approximately 15,000 in recent years.This influx of innovation spearheaded by companies such as Hitachi and Fujifilm is driving the market forward as new and improved diagnostics tools become available, enabling high accuracy and speed in patient testing. **Government Initiatives and Policies for Healthcare Reform** Government initiatives and policies in Japan aimed at healthcare reform are significantly influencing the Japan Rapid Diagnostics Market Industry. The Japanese government has set ambitious goals to reduce healthcare costs while improving quality, driving public bodies to adopt advanced diagnostic methods. With a projected increase in healthcare spending of approximately 2.5% annually, as indicated in the Health Ministry's budget plans, the market for rapid diagnostics is expected to thrive.Initiatives like the 'Future Investment Strategy' underline the importance of integrating rapid diagnostics into national health systems to improve overall efficiency and effectiveness in patient care. **Increase in Infectious Disease Outbreaks** The increase in infectious disease outbreaks, highlighted by incidents such as the COVID-19 pandemic, has sparked an urgent need for rapid diagnostic tests in Japan. Historical data from the Japan National Institute of Infectious Diseases indicates a significant rise in demand for rapid diagnostic solutions during outbreak scenarios, with COVID-19 testing tripling the market size for these products within a short span. Organizations like the Japan Association of Medical Technologists emphasize the necessity for rapid and reliable diagnostics to effectively control infectious disease spread, contributing to sustained growth in the rapid diagnostics market. **Japan Rapid Diagnostics Market Segment Insights** **Rapid Diagnostics Market Application Insights** The Application segment of the Japan Rapid Diagnostics Market encompasses a wide variety of testing methods critical for timely and accurate health assessments. With the growing prevalence of chronic diseases and the increasing emphasis on preventive healthcare, the significance of blood glucose testing cannot be understated; it plays a central role in diabetes management, which is a significant concern in Japan due to its aging population. Infectious Disease Testing remains crucial, particularly in light of recent global health challenges, driving continuous innovation in rapid test kits that help in early diagnosis and containment of outbreaks.Cardiometabolic Testing holds relevance as rising obesity rates and cardiovascular diseases are on the rise, making early detection essential for effective interventions.  Pregnancy Fertility Testing is increasingly sought after in a society that values reproductive health and family planning, thus accommodating modern lifestyles and demographics. Fecal Occult Blood Testing serves as a pivotal screening method for colorectal cancer, enhancing preventive care among the aging population in Japan, which speaks to the region's proactive health strategies.Coagulation Testing is vital for patients on anticoagulation therapies, thus answering the needs of a population that is increasingly attentive to blood-related disorders.  Lastly, Toxicology Testing contributes to public safety and health by identifying substance use, ensuring regulatory compliance, and enhancing workplace safety, aligning with Japan's stringent health standards. Collectively, these areas not only reflect the multifaceted nature of healthcare needs in Japan but also present substantial opportunities for innovations in the Rapid Diagnostics Market, driven by technology advancements and a focus on point-of-care testing capabilities, which are integral to improving healthcare outcomes efficiently. **Rapid Diagnostics Market Product Type Insights** The Japan Rapid Diagnostics Market is characterized by a growing segmentation focused on Product Types, primarily divided into Over the Counter (OTC) Kits and Professional Kits. The OTC Kits segment has exhibited significant traction due to its ease of access and convenience, allowing individuals to perform testing in the comfort of their homes. This has become particularly important during health crises, such as infectious disease outbreaks, as they facilitate quick decision-making and early intervention. Conversely, Professional Kits dominate the clinical setting, providing enhanced accuracy and reliability required for healthcare professionals to make informed diagnoses.The shifting consumer preferences towards self-testing and the rising awareness of preventive healthcare are key drivers boosting the demand for these testing kits.  Furthermore, Japan's aging population amplifies the need for rapid diagnostics, leveraging both OTC and Professional options to manage and monitor health conditions effectively. The focus on innovative technologies, combined with a robust regulatory environment, fosters a dynamic market landscape where adaptability and safety remain paramount. Both segments play integral roles in the overall ecosystem of the Japan Rapid Diagnostics Market, catering to distinct consumer needs while contributing significantly to public health initiatives. **Japan Rapid Diagnostics Market Key Players and Competitive Insights** The Japan Rapid Diagnostics Market has experienced significant growth due to the increasing demand for timely and efficient healthcare solutions. The competitive landscape is characterized by various companies striving to innovate and meet the needs of healthcare professionals and patients alike. Rapid diagnostics tests have become critical in decision-making processes across various medical fields, including infectious diseases, chronic diseases, and other health-related conditions. The landscape is marked by the presence of both established players and emerging companies, all vying for market share through the introduction of novel testing technologies and improved service offerings. The innovation within this sector is fostering competition that drives down costs while enhancing accuracy and speed, thereby reshaping how diagnostics are conducted in Japan. Mitsubishi Chemical Corporation plays a prominent role in the Japan Rapid Diagnostics Market, leveraging its extensive experience and advanced technology infrastructure. The company has developed a range of diagnostic solutions focusing on rapid detection and analysis, which are well-suited to the needs of healthcare facilities. Mitsubishi Chemical Corporation stands out due to its strong research and development capabilities, enabling it to produce high-quality and reliable diagnostic products. Furthermore, the company's established brand reputation and distribution networks give it a competitive edge. With a commitment to innovation, Mitsubishi Chemical Corporation continuously invests in advanced testing technologies and methodologies, ensuring that it remains a key player in the evolving landscape of rapid diagnostics in Japan. Fujirebio is another significant competitor in the Japan Rapid Diagnostics Market, known for its expertise in biomarker discovery and development. The company offers a range of diagnostic products, particularly focusing on immunoassays that cater to various medical conditions. Fujirebio's strong market presence in Japan is bolstered by its innovative product line, which includes tests for infectious diseases and cancer markers. The company has made strategic mergers and acquisitions to enhance its capabilities, further cementing its position in the market.  Additionally, Fujirebio invests heavily in research and technological advancement, enabling it to provide accurate and timely diagnostics, which are essential for effective patient management in Japan. The company's methodical approach to product development, along with its established reputation, positions it as a formidable competitor in the rapidly evolving diagnostics landscape. **Key Companies in the Japan Rapid Diagnostics Market Include:** - Mitsubishi Chemical Corporation - Fujirebio - Sysmex Corporation - Grifols - Denka Company Limited - Roche Diagnostics - Arkray - Ameditech - Quidel Corporation - Thermo Fisher Scientific - Abbott Laboratories - Takara Bio - BioRad Laboratories - Hepalink - Mylan **Japan Rapid Diagnostics Market Industry Developments** The Japan Rapid Diagnostics Market has seen significant developments recently, particularly in the context of increased demand for COVID-19 testing and other diagnostic services. Companies like Mitsubishi Chemical Corporation and Fujirebio are expanding their product offerings to meet these needs. In October 2023, Sysmex Corporation announced advancements in their diagnostics technologies, enabling faster and more accurate test results.  Furthermore, Roche Diagnostics and Abbott Laboratories are investing in research and development to enhance their rapid testing capabilities. In terms of acquisitions, Fujirebio recently acquired a smaller diagnostics firm in September 2023, which has fortified its position in the market and broadened its product range. Significant growth in market valuation has been observed, driven by technological advancements and the urgent need for efficient diagnostics, especially in light of recent health crises.  In the last few years, particularly since 2021, companies such as Quidel Corporation and Thermo Fisher Scientific have strengthened their market presence through strategic partnerships and innovations. Collectively, these movements reflect the dynamic nature of Japan's rapid diagnostics landscape, responding promptly to public health needs and enhancing healthcare outcomes. **Japan Rapid Diagnostics Market Segmentation Insights** - **Rapid Diagnostics Market Application Outlook** - Blood Glucose Testing - Infectious Disease Testing - Cardiometabolic Testing - PregnancyFertility Testing - Fecal Occult Blood Testing - Coagulation Testing - Toxicology Testing - **Rapid Diagnostics Market Product Type Outlook** - Over the Counter (OTC) Kits - Professional Kits ## Market Drivers ### Government Initiatives and Funding Government initiatives aimed at improving healthcare infrastructure are significantly impacting the rapid diagnostics market. In Japan, the government has been actively investing in healthcare technologies to enhance disease detection and management. Recent policies have allocated substantial funding to support the development of rapid diagnostic tools, which are essential for timely medical interventions. The rapid diagnostics market is likely to benefit from these initiatives, as they promote innovation and accessibility to advanced diagnostic solutions. For instance, the Ministry of Health, Labour and Welfare has set a target to increase the availability of rapid testing kits in healthcare facilities by 30% over the next five years. This commitment underscores the government's role in fostering a conducive environment for market growth. ### Rising Prevalence of Chronic Diseases The increasing prevalence of chronic diseases in Japan is a crucial driver for the rapid diagnostics market. As the population ages, conditions such as diabetes, cardiovascular diseases, and respiratory disorders become more common. This trend necessitates timely and accurate diagnostic solutions to manage these health issues effectively. The rapid diagnostics market is likely to see a surge in demand for tests that can provide quick results, enabling healthcare providers to make informed decisions. According to recent estimates, chronic diseases account for approximately 60% of all deaths in Japan, highlighting the urgent need for efficient diagnostic tools. Consequently, the market is expected to grow as healthcare systems adapt to these challenges, focusing on early detection and management of chronic conditions. ### Aging Population and Healthcare Demand Japan's aging population is a pivotal driver for the rapid diagnostics market. With a significant portion of the population over the age of 65, there is an increasing demand for healthcare services, including diagnostic testing. The rapid diagnostics market is responding to this demographic shift by developing tests that cater specifically to age-related health issues. As older adults often require more frequent health assessments, the need for rapid and reliable diagnostic tools is becoming more pronounced. Projections suggest that the market could expand by approximately 20% over the next five years, driven by the necessity for efficient healthcare solutions tailored to the elderly. This demographic trend underscores the importance of rapid diagnostics in managing the health of Japan's aging population. ### Technological Integration in Healthcare The integration of advanced technologies in healthcare is transforming the rapid diagnostics market. Innovations such as artificial intelligence, machine learning, and point-of-care testing devices are enhancing the accuracy and speed of diagnostic processes. In Japan, the adoption of these technologies is becoming increasingly prevalent, as healthcare providers seek to improve patient outcomes and streamline operations. The rapid diagnostics market is experiencing a shift towards more sophisticated testing methods, which can deliver results in real-time. This technological evolution is projected to drive market growth, with investments in research and development expected to reach approximately ¥100 billion by 2026. As a result, the landscape of diagnostics is evolving, making it essential for stakeholders to stay abreast of these advancements. ### Consumer Awareness and Health Consciousness There is a growing trend of health consciousness among consumers in Japan, which is driving the rapid diagnostics market. As individuals become more aware of their health and the importance of early detection, the demand for rapid diagnostic tests is increasing. This shift in consumer behavior is prompting healthcare providers to offer more accessible testing options. The rapid diagnostics market is witnessing a rise in home testing kits and point-of-care solutions, catering to the needs of health-conscious individuals. Market Research Future indicates that approximately 45% of Japanese consumers are now willing to invest in at-home diagnostic tests, reflecting a significant change in attitudes towards personal health management. This trend is expected to continue, further propelling the market forward. ## Future Outlook The [Rapid Diagnostics Market](https://www.marketresearchfuture.com/reports/rapid-diagnostics-market-11687) in Japan is projected to grow at an 8.8% CAGR from 2025 to 2035, driven by technological advancements, increasing healthcare demands, and regulatory support. **New opportunities:** - Development of portable diagnostic devices for remote healthcare settings. Integration of AI-driven analytics in diagnostic processes. Expansion of telehealth services incorporating rapid testing solutions. By 2035, the rapid diagnostics market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Product: Over-the-Counter Kits (Largest) vs. Professional Kits (Fastest-Growing) In the Japan rapid diagnostics market, Over-the-Counter (OTC) Kits hold the largest share, attributed to their ease of accessibility and growing consumer preference for self-testing solutions. These kits are widely utilized for various diagnostic purposes, leading to their dominant presence in the market. In contrast, Professional Kits cater to healthcare institutions and laboratories, contributing significantly to the growth dynamics of the market. The growth trends in this segment are propelled by the increasing demand for rapid and accurate diagnostic solutions. Factors such as the rising health consciousness among consumers, advancements in diagnostic technology, and the ongoing emphasis on preventive healthcare are driving the adoption of both OTC and Professional Kits. As the market evolves, Professional Kits are expected to witness the fastest growth due to their integration into clinical workflows and reliance on accurate diagnostics in patient care. Over-the-Counter Kits (Dominant) vs. Professional Kits (Emerging) Over-the-Counter Kits are characterized by their convenience and accessibility for end-users, making them the dominant segment in the market. These kits allow individuals to conduct tests at home without needing professional assistance, thus promoting public health awareness. On the other hand, Professional Kits serve a critical role in clinical settings, offering precise and reliable results for healthcare providers. Although Professional Kits are currently emerging, their growth is driven by the need for efficient diagnostic processes in laboratories and hospitals. The introduction of innovative testing methods and technologies continues to enhance their appeal, positioning them as a vital component of the evolving landscape in the Japan rapid diagnostics market. ### By Application: Blood Glucose Testing (Largest) vs. Infectious Disease Testing (Fastest-Growing) Within the Japan rapid diagnostics market, Blood Glucose Testing holds the largest share due to the increasing prevalence of diabetes and a growing focus on home healthcare. This segment outperforms others, with a strong demand driven by rising awareness among patients and healthcare providers about the necessity of regular monitoring. On the other hand, Infectious Disease Testing is witnessing rapid growth as awareness of infectious diseases, including infectious outbreaks, is on the rise. Technological advancements and the integration of rapid test kits have further stimulated this growth. The increased need for rapid results in clinical settings fuels investments in this area, making it a critical focus for industry stakeholders. Blood Glucose Testing: Dominant vs. Infectious Disease Testing: Emerging Blood Glucose Testing stands out as the dominant segment within the Japan rapid diagnostics market, largely attributed to the widespread adoption of self-monitoring glucose devices among diabetes patients. This segment benefits from proactive healthcare measures and a strong emphasis on patient education. Conversely, Infectious Disease Testing represents the emerging trend, capitalizing on technological innovations that enhance speed and accuracy. The segment is becoming increasingly vital amid public health initiatives aimed at controlling disease outbreaks, showing potential for rapid introduction of new tests. Together, these segments illustrate the dynamic evolution in diagnostic needs, balancing chronic disease management with the urgency of infectious disease detection. ## Competitive Benchmarking The [rapid diagnostics market](https://www.marketresearchfuture.com/reports/rapid-diagnostics-market-11687)in Japan is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing demand for timely and accurate diagnostic solutions. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are at the forefront, each adopting distinct strategies to enhance their market presence. Abbott Laboratories (US) focuses on innovation, particularly in point-of-care testing, which aligns with the growing trend towards decentralized healthcare. Roche Diagnostics (CH) emphasizes partnerships and collaborations to expand its diagnostic portfolio, while Siemens Healthineers (DE) is investing heavily in digital transformation to streamline operations and improve diagnostic accuracy. Collectively, these strategies contribute to a competitive environment that is increasingly centered on technological innovation and strategic partnerships.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for niche players to thrive, while larger corporations leverage their resources to capture a more significant market share. The interplay between these dynamics shapes the overall competitive landscape, fostering an environment where innovation and operational excellence are paramount. In October Roche Diagnostics (CH) announced a strategic partnership with a leading Japanese biotechnology firm to co-develop next-generation rapid diagnostic tests. This collaboration is expected to enhance Roche's capabilities in the Japanese market, allowing for localized product development that meets specific regional needs. The strategic importance of this partnership lies in its potential to accelerate the introduction of innovative diagnostic solutions, thereby strengthening Roche's competitive position in Japan. In September Siemens Healthineers (DE) launched a new digital platform aimed at integrating artificial intelligence into its diagnostic processes. This platform is designed to improve the accuracy and speed of diagnostics, which is increasingly critical in a market that values rapid results. The introduction of AI-driven solutions signifies Siemens' commitment to leading the digital transformation in healthcare, positioning the company as a forward-thinking player in the rapid diagnostics sector. In August Abbott Laboratories (US) expanded its manufacturing capabilities in Japan, investing approximately $50 million to enhance production of its rapid testing devices. This expansion not only increases Abbott's capacity to meet local demand but also underscores the company's long-term commitment to the Japanese market. The strategic importance of this investment lies in its potential to improve supply chain reliability and reduce lead times, which are crucial in the fast-paced diagnostics environment. As of November current trends in the rapid diagnostics market are heavily influenced by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming increasingly vital, as companies seek to leverage complementary strengths to enhance their offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This shift indicates a market poised for transformation, where the ability to deliver cutting-edge solutions will define success. ## Recent News & Developments The Japan Rapid Diagnostics Market has seen significant developments recently, particularly in the context of increased demand for COVID-19 testing and other diagnostic services. Companies like Mitsubishi Chemical Corporation and Fujirebio are expanding their product offerings to meet these needs. In October 2023, Sysmex Corporation announced advancements in their diagnostics technologies, enabling faster and more accurate test results.  Furthermore, Roche Diagnostics and Abbott Laboratories are investing in research and development to enhance their rapid testing capabilities. In terms of acquisitions, Fujirebio recently acquired a smaller diagnostics firm in September 2023, which has fortified its position in the market and broadened its product range. Significant growth in market valuation has been observed, driven by technological advancements and the urgent need for efficient diagnostics, especially in light of recent health crises.  In the last few years, particularly since 2021, companies such as Quidel Corporation and Thermo Fisher Scientific have strengthened their market presence through strategic partnerships and innovations. Collectively, these movements reflect the dynamic nature of Japan's rapid diagnostics landscape, responding promptly to public health needs and enhancing healthcare outcomes. ## Report Scope | MARKET SIZE 2024 | 1414.93(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1539.45(USD Million) | | MARKET SIZE 2035 | 3577.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.8% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), bioMérieux (FR), Cepheid (US), Hologic, Inc. (US), Ortho Clinical Diagnostics (US) | | Segments Covered | Product, Application | | Key Market Opportunities | Integration of artificial intelligence in rapid diagnostics enhances accuracy and efficiency in patient care. | | Key Market Dynamics | Technological advancements drive rapid diagnostics market growth, enhancing accuracy and speed in disease detection. | | Countries Covered | Japan | ## Frequently Asked Questions **Q: What is the current valuation of the Japan rapid diagnostics market?** A: The market valuation was $1414.93 Million in 2024. **Q: What is the projected market size for the Japan rapid diagnostics market by 2035?** A: The market is projected to reach $3577.0 Million by 2035. **Q: What is the expected CAGR for the Japan rapid diagnostics market during the forecast period 2025 - 2035?** A: The expected CAGR is 8.8% during the forecast period. **Q: Which companies are the key players in the Japan rapid diagnostics market?** A: Key players include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific. **Q: What are the main product segments in the Japan rapid diagnostics market?** A: The main product segments are Over-the-Counter (OTC) Kits and Professional Kits. **Q: What was the market size for Over-the-Counter (OTC) Kits in 2024?** A: The market size for OTC Kits was between $500.0 Million and $1200.0 Million in 2024. **Q: What is the market size for Professional Kits in 2024?** A: The market size for Professional Kits ranged from $914.93 Million to $2377.0 Million in 2024. **Q: Which application segments are included in the Japan rapid diagnostics market?** A: Application segments include Blood Glucose Testing, Infectious Disease Testing, and Cardiometabolic Testing. **Q: What was the market size for Infectious Disease Testing in 2024?** A: The market size for Infectious Disease Testing was between $400.0 Million and $1000.0 Million in 2024. **Q: What is the expected growth trend for the Japan rapid diagnostics market?** A: The market is likely to experience robust growth, reaching $3577.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/japan-rapid-diagnostics-market-45345*